Lv5
936 积分 2021-03-16 加入
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
1个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
1个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
3个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
3个月前
已完结
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
3个月前
已完结
Weight management treatment in obesity
4个月前
已完结
Genomic Analysis and Engineering of Chinese Hamster Ovary Cells for Improved Therapeutic Protein Production
4个月前
已完结
Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys
5个月前
已完结
Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex
5个月前
已完结
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial
5个月前
已完结
皖公网安备34019202002308
